Amgen Company Leadership

AMGN Stock  USD 274.73  1.19  0.44%   
About 67% of Amgen's corporate insiders are selling. The analysis of the overall insider sentiment regarding Amgen Inc suggests that many insiders are alarmed. Amgen employs about 26.7 K people. The company is managed by 44 executives with a total tenure of roughly 397 years, averaging almost 9.0 years of service per executive, having 606.82 employees per reported executive.
Robert Bradway  Chairman
Chairman, CEO and President Chairman of Executive Committee and Member of Equity Award Committee
David Reese  President
Executive Vice President - Research and Development

Amgen's Insider Buying Vs Selling

33

 
Selling
 
Buying

Latest Trades

2024-01-23Kathy E. ManningAcquired @ 309.91
2024-01-19Tommy TubervilleDisposed @ 307.81
2024-01-02Michael C. BurgessDisposed @ 297.39
2023-12-04Nancy A GrygielDisposed 2096 @ 273.03View
2023-11-08Jonathan P GrahamDisposed 10000 @ 272.81View
2023-10-24Greg StantonDisposed @ 276.12
2023-09-26Greg StantonAcquired @ 269.04
2023-09-19Amgen IncAcquired 1764705 @ 17View
2023-08-10Murdo GordonDisposed 9558 @ 262.43View
Monitoring Amgen's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.

Acquired vs Disposed

Filed vs Not Filed

Insider sentiment refers to the collective sentiment or feeling of Amgen's insiders - typically its officers, directors, and beneficial owners holding more than a certain percentage of the company's stock - about the future prospects of Amgen Inc. This sentiment is often gauged based on the trading activities of these insiders. If insiders are purchasing more shares of their own company, it may be interpreted as a bullish sentiment, indicating that they believe Amgen's stock will rise in value. Conversely, if insiders are selling shares, it might be seen as bearish, suggesting they expect the stock price to drop.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amgen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.

Amgen's latest congressional trading

Congressional trading in companies like Amgen Inc, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Amgen by those in governmental positions are based on the same information available to the general public.
2024-01-19Senator Thomas H TubervilleAcquired $15K to $50KVerify
2023-09-26Representative Greg StantonAcquired Under $15KVerify
2023-06-12Senator Shelley M CapitoAcquired Under $15KVerify
2022-10-06Senator Tommy TubervilleAcquired Under $15KVerify
2022-09-26Representative Earl BlumenauerAcquired Under $15KVerify
2022-02-22Representative Marjorie Taylor GreeneAcquired Under $15KVerify
2021-03-04Representative Carol Devine MillerAcquired $15K to $50KVerify
2021-02-16Representative Peter MeijerAcquired Under $15KVerify
2021-02-05Representative Kurt SchraderAcquired Under $15KVerify
2020-11-05Senator Bill CassidyAcquired Under $15KVerify
2020-04-07Senator Kelly LoefflerAcquired $15K to $50KVerify
2020-02-20Representative Mikie SherrillDisposed Under $15KVerify
2019-09-19Representative Bill FloresAcquired Under $15KVerify
2019-08-28Representative Richard W. AllenAcquired $15K to $50KVerify
2019-02-04Senator Jack ReedAcquired Under $15KVerify
2018-10-05Representative Gary PalmerAcquired Under $15KVerify
2018-04-24Senator Shelley Moore CapitoAcquired Under $15KVerify
2017-05-30Senator James M. InhofeAcquired $50K to $100KVerify
2017-01-20Senator John HoevenAcquired $50K to $100KVerify
2016-04-12Senator Sheldon WhitehouseAcquired Under $15KVerify

Amgen Management Team Effectiveness

The company has return on total asset (ROA) of 0.0629 % which means that it generated a profit of $0.0629 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 1.3579 %, meaning that it created $1.3579 on every $100 dollars invested by stockholders. Amgen's management efficiency ratios could be used to measure how well Amgen manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Amgen's Return On Assets are very stable compared to the past year. As of the 24th of April 2024, Return On Equity is likely to grow to 1.13, while Return On Tangible Assets are likely to drop 0.12. At this time, Amgen's Return On Assets are very stable compared to the past year. As of the 24th of April 2024, Asset Turnover is likely to grow to 0.51, while Other Current Assets are likely to drop about 266.9 M.
As of the 24th of April 2024, Common Stock Shares Outstanding is likely to grow to about 759.2 M, while Net Income Applicable To Common Shares is likely to drop about 5 B.

Amgen Workforce Comparison

Amgen Inc is rated below average in number of employees category among related companies. The total workforce of Health Care industry is presently estimated at about 469,270. Amgen holds roughly 26,700 in number of employees claiming about 6% of equities under Health Care industry.

Amgen Profit Margins

The company has Profit Margin (PM) of 0.24 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.08 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.08.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.650.7002
Significantly Down
Slightly volatile
Net Profit Margin0.180.2383
Way Down
Pretty Stable
Pretax Profit Margin0.250.2786
Moderately Down
Pretty Stable
Return On Assets0.120.0691
Way Up
Slightly volatile
Return On Equity1.131.0778
Sufficiently Up
Slightly volatile

Amgen Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Amgen insiders, such as employees or executives, is commonly permitted as long as it does not rely on Amgen's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Amgen insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-03-01
1.2
12
10
 128,172 
 52,169 
2023-12-01
0.2727
3
11
 778.18 
 18,395 
2023-09-01
1.0
3
3
 402.61 
 10,687 
2023-06-01
1.0938
35
32
 343,194 
 24,751 
2023-03-01
1.0
10
10
 69,837 
 33,994 
2022-12-01
0.3
3
10
 615.62 
 8,687 
2022-09-01
0.5
4
8
 20,896 
 55,437 
2022-06-01
0.8919
33
37
 472,935 
 107,264 
2022-03-01
0.9
9
10
 77,529 
 36,444 
2021-12-01
1.2
6
5
 3,728 
 13,381 
2021-09-01
1.5
3
2
 1,390 
 0.00 
2021-06-01
0.9459
35
37
 375,777 
 40,250 
2021-03-01
0.6818
15
22
 165,980 
 186,952 
2020-12-01
0.6667
2
3
 1,594 
 8,644 
2020-09-01
0.625
5
8
 10,823 
 6,705 
2020-06-01
0.9189
34
37
 459,197 
 205,597 
2020-03-01
0.6923
9
13
 100,324 
 61,126 
2019-12-01
0.6667
8
12
 30,013 
 47,893 
2019-09-01
0.5385
7
13
 14,877 
 37,554 
2019-06-01
1.2222
33
27
 419,231 
 40,214 
2019-03-01
0.6111
11
18
 96,210 
 56,365 
2018-12-01
1.0
7
7
 75,562 
 54,163 
2018-09-01
0.5714
4
7
 3,919 
 21,452 
2018-06-01
1.5
33
22
 1,480,178 
 2,297,615 
2018-03-01
0.3478
8
23
 110,457 
 66,595 
2017-06-01
3.0
36
12
 441,529 
 10,778 
2017-03-01
0.3333
9
27
 158,860 
 94,677 
2016-12-01
0.25
1
4
 355.00 
 3,152 
2016-09-01
0.1429
1
7
 5,000 
 24,198 
2016-06-01
1.8947
36
19
 425,332 
 69,131 
2016-03-01
0.4706
16
34
 425,541 
 361,181 
2015-09-01
0.8333
5
6
 57,219 
 28,145 
2015-06-01
0.5806
18
31
 38,722 
 102,954 
2015-03-01
0.675
27
40
 551,241 
 401,723 
2014-12-01
0.0833
1
12
 309.00 
 43,542 
2014-09-01
0.4615
6
13
 86,163 
 73,354 
2014-06-01
0.3488
15
43
 23,471 
 34,336 
2014-03-01
0.9615
25
26
 265,182 
 248,416 
2013-12-01
1.0
3
3
 14,785 
 13,421 
2013-09-01
0.4
2
5
 36,000 
 59,492 
2013-06-01
0.4667
28
60
 94,492 
 241,160 
2013-03-01
1.2
18
15
 172,646 
 82,420 
2012-12-01
0.5
6
12
 76,420 
 148,271 
2012-09-01
0.6604
35
53
 849,170 
 1,364,514 
2012-06-01
0.6964
39
56
 203,732 
 270,446 
2012-03-01
0.75
36
48
 522,700 
 839,960 
2011-12-01
1.0
7
7
 32,114 
 82,461 
2011-09-01
0.9
9
10
 25,651 
 67,079 
2011-06-01
1.1515
38
33
 414,048 
 76,095 
2011-03-01
0.8889
8
9
 67,836 
 39,746 
2010-12-01
1.0
4
4
 300,900 
 16,050 
2010-09-01
0.1667
2
12
 21,583 
 50,197 
2010-06-01
1.2903
40
31
 654,123 
 40,106 
2010-03-01
0.5652
13
23
 105,580 
 120,656 
2009-12-01
0.0588
1
17
 800.00 
 23,705 
2009-09-01
0.5
2
4
 25,106 
 8,610 
2009-06-01
1.4815
40
27
 619,470 
 127,363 
2009-03-01
0.0476
1
21
 16,000 
 48,536 
2008-12-01
0.1183
11
93
 257,001 
 442,548 
2008-09-01
0.1667
1
6
 20,500 
 7,680 
2008-06-01
1.1429
32
28
 701,743 
 380,336 
2007-12-01
1.5
3
2
 34,634 
 36,908 
2007-09-01
0.3333
1
3
 25,000 
 51,340 
2007-06-01
1.3
26
20
 478,088 
 374,273 
2006-12-01
0.1522
7
46
 136,859 
 270,008 
2006-06-01
0.2895
11
38
 256,500 
 268,262 
2006-03-01
0.2899
20
69
 95,091 
 232,607 
2005-12-01
0.1148
7
61
 188,423 
 423,722 
2005-09-01
0.2414
14
58
 607,103 
 1,198,115 
2005-06-01
0.2917
7
24
 805,749 
 1,054,848 
2005-03-01
1.0
28
28
 1,525,261 
 1,411,655 
2004-12-01
0.2222
6
27
 159,198 
 478,397 
2004-09-01
0.2308
6
26
 81,572 
 523,297 
2004-06-01
0.4286
9
21
 21,000 
 129,787 
2004-03-01
1.0
33
33
 493,017 
 336,934 
2003-12-01
0.0857
3
35
 22,762 
 302,192 
2003-09-01
0.5938
19
32
 840,770 
 462,676 

Amgen Notable Stakeholders

An Amgen stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Amgen often face trade-offs trying to please all of them. Amgen's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Amgen's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Robert BradwayChairman, CEO and President Chairman of Executive Committee and Member of Equity Award CommitteeProfile
David ReeseExecutive Vice President - Research and DevelopmentProfile
Brian McNameeExecutive Vice President - Full Potential InitiativesProfile
Esteban SantosExecutive Vice President OperationsProfile
Jonathan GrahamSenior Vice President General Counsel, SecretaryProfile
Sean HarperExecutive Vice President - Research and DevelopmentProfile
Stuart TrossSenior Vice President - Human ResourcesProfile
Murdo GordonExecutive Vice President of Global Commercial OperationsProfile
Lori JohnstonSenior Vice President - Human ResourcesProfile
Cynthia PattonSenior Vice President Chief Compliance OfficerProfile
David PiacquadSenior Vice President - Business DevelopmentProfile
David MelineCFO and Executive VPProfile
Peter GriffithExecutive CFOProfile
Madhavan BalachandranExecutive VP of OperationsProfile
Anthony HooperExecutive VP of Global Commercial OperationsProfile
Frank HerringerIndependent DirectorProfile
Francois CarbonnelIndependent DirectorProfile
Rebecca HendersonIndependent DirectorProfile
Sanders WilliamsIndependent DirectorProfile
Vance CoffmanLead Independent DirectorProfile
Tyler JacksIndependent DirectorProfile
Gregory GarlandIndependent DirectorProfile
Charles HolleyDirectorProfile
Ellen KullmanDirectorProfile
Frank BiondiIndependent DirectorProfile
Ronald SugarIndependent DirectorProfile
Wanda AustinIndependent DirectorProfile
Robert EckertIndependent DirectorProfile
Brian DrukerIndependent DirectorProfile
Greg GarlandIndependent DirectorProfile
Robert WilliamsIndependent DirectorProfile
Judith PelhamIndependent DirectorProfile
David BaltimoreIndependent DirectorProfile
Fred HassanDirectorProfile
Linda LouieVP OfficerProfile
James MDExecutive OfficerProfile
Nancy GrygielSenior OfficerProfile
Annette SuchChief Accounting OfficerProfile
Mike ZahigianSenior OfficerProfile
Arvind SoodIR Contact OfficerProfile
Justin ClaeysVice RelationsProfile
Matthew BuschChief FinanceProfile
Alan RussellVice BiologicsProfile
David MDExecutive OfficerProfile

About Amgen Management Performance

The success or failure of an entity such as Amgen Inc often depends on how effective the management is. Amgen management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Amgen management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Amgen management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets 0.15  0.12 
Return On Capital Employed 0.10  0.1 
Return On Assets 0.07  0.12 
Return On Equity 1.08  1.13 
The data published in Amgen's official financial statements usually reflect Amgen's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Amgen Inc. For example, before you start analyzing numbers published by Amgen accountants, it's critical to develop an understanding of what Amgen's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Amgen's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Amgen's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Amgen's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Amgen Inc. Please utilize our Beneish M Score to check the likelihood of Amgen's management manipulating its earnings.

Amgen Workforce Analysis

Traditionally, organizations such as Amgen use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Amgen within its industry.

Amgen Manpower Efficiency

Return on Amgen Manpower

Revenue Per Employee1.1M
Revenue Per Executive640.7M
Net Income Per Employee251.6K
Net Income Per Executive152.7M
Working Capital Per Employee447.2K
Working Capital Per Executive271.4M
When determining whether Amgen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Amgen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Amgen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Amgen Inc Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amgen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.
Note that the Amgen Inc information on this page should be used as a complementary analysis to other Amgen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Complementary Tools for Amgen Stock analysis

When running Amgen's price analysis, check to measure Amgen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amgen is operating at the current time. Most of Amgen's value examination focuses on studying past and present price action to predict the probability of Amgen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amgen's price. Additionally, you may evaluate how the addition of Amgen to your portfolios can decrease your overall portfolio volatility.
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Is Amgen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amgen. If investors know Amgen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amgen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.52)
Dividend Share
8.52
Earnings Share
12.5
Revenue Per Share
52.692
Quarterly Revenue Growth
0.198
The market value of Amgen Inc is measured differently than its book value, which is the value of Amgen that is recorded on the company's balance sheet. Investors also form their own opinion of Amgen's value that differs from its market value or its book value, called intrinsic value, which is Amgen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amgen's market value can be influenced by many factors that don't directly affect Amgen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amgen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Amgen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amgen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.